New Results
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors
Inga H. Rye, Anne Trinh, Anna Sætersdal, Daniel Nebdal, Ole Christian Lingjærde, Vanessa Almendro, Kornelia Polyak, Anne-Lise Børresen-Dale, Åslaug Helland, View ORCID ProfileFlorian Markowetz, Hege G. Russnes
doi: https://doi.org/10.1101/297549
Inga H. Rye
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
Anne Trinh
bUniversity of Cambridge, Cancer Research UK, Cambridge Institute, Cambridge, UK
Anna Sætersdal
cInstitute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
Daniel Nebdal
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
Ole Christian Lingjærde
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
dBiomedical Informatics Division, Department of Computer Science, University of Oslo, Oslo, Norway
Vanessa Almendro
fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
Kornelia Polyak
fDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
Anne-Lise Børresen-Dale
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
gDepartment of Clinical Medicine, University of Oslo, Norway.
Åslaug Helland
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
cInstitute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
gDepartment of Clinical Medicine, University of Oslo, Norway.
Florian Markowetz
bUniversity of Cambridge, Cancer Research UK, Cambridge Institute, Cambridge, UK
Hege G. Russnes
aDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
eDepartment of Pathology, Oslo University Hospital, Oslo, Norway
Article usage
Posted April 18, 2018.
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors
Inga H. Rye, Anne Trinh, Anna Sætersdal, Daniel Nebdal, Ole Christian Lingjærde, Vanessa Almendro, Kornelia Polyak, Anne-Lise Børresen-Dale, Åslaug Helland, Florian Markowetz, Hege G. Russnes
bioRxiv 297549; doi: https://doi.org/10.1101/297549
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors
Inga H. Rye, Anne Trinh, Anna Sætersdal, Daniel Nebdal, Ole Christian Lingjærde, Vanessa Almendro, Kornelia Polyak, Anne-Lise Børresen-Dale, Åslaug Helland, Florian Markowetz, Hege G. Russnes
bioRxiv 297549; doi: https://doi.org/10.1101/297549
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8722)
- Bioinformatics (29127)
- Biophysics (14932)
- Cancer Biology (12048)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12220)
- Genomics (16766)
- Immunology (11841)
- Microbiology (28005)
- Molecular Biology (11552)
- Neuroscience (60808)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4939)
- Plant Biology (10384)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)